Reproducibility of histological cell type in high-grade endometrial carcinoma

Modern Pathology

Volumn 26, Issue 12, 2013, Pages 1594-1604

  Han, Guangming ^a   Sidhu, Davinder ^b   Duggan, Máire A ^b   Arseneau, Jocelyne ^c   Cesari, Matthew ^a   Clement, Philip B ^d   Ewanowich, Carol A ^e   Kalloger, Steve E ^d   Köbel, Martin ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Carcinoma; Endometrial; Endometrioid; Immunohistochemistry; Interobserver agreement; Reproducibility; Serous

Indexed keywords

BETA CATENIN; ESTROGEN; HEPATOCYTE NUCLEAR FACTOR 1BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; TUMOR MARKER; VIMENTIN;

ADULT; AGED; ARTICLE; CANADA; CANCER DIAGNOSIS; CANCER GRADING; CELL TYPE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889082719     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.102     Document Type: Article

References (33)

1. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol 2010;34: 984-993.
2. Nedergaard L, Jacobsen M, Andersen JE. Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas. APMIS 1995;103: 511-518.
3. Gilks CB. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Mod Pathol 2011;24:248A.
4. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002;9:145-184.
5. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004;11:117-142.
6. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;28:1568-1578. (Pubitemid 39564961)
7. Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol 2010;27:261-273.
8. Garg K, Soslow RA. Strategies for distinguishing lowgrade endometrioid and serous carcinomas of endometrium. Adv Anat Pathol 2012;19:1-10.
9. Fadare O, Parkash V, Dupont WD, et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol 2012;36:1107-1118.
10. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24: 4783-4791. (Pubitemid 46630943)
11. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011;224:328-333.
12. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011;223:567-573.
13. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20-30.
14. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012;104:1503-1513.
15. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012; 44:1310-1315.
16. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92: 924-930.
17. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008;32:304-315. (Pubitemid 351172146)
18. Lomo L, Nucci MR, Lee KR, et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol 2008;21:937-942.
19. Garg K, Leitao MM, Wynveen CA, et al. P53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 2010;23:80-92.
20. Yemelyanova A, Ji H, Shih IM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009;33:1504-1514.
21. Alkushi A, Köbel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29: 343-350.
22. Djordjevic B, Hennessy BT, Li J, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 2012;25:699-708.
23. Kalloger SE, Köbel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011;24:512-521.
24. Köbel M, Reuss A, Bois AD, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-198.
25. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85:257-268. (Pubitemid 40333545)
26. Horn LC, Richter CE, Einenkel J, et al. P16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. Ann Diagn Pathol 2006;10:193-196. (Pubitemid 44038399)
27. Silva EG, Deavers MT, Bodurka DC, et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25:52-58. (Pubitemid 44638336)
28. Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010;23:781-789.
29. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010;29:203-211.
30. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161-174. (Pubitemid 351450675)
31. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010;220:392-400.
32. Zheng W, Xiang L, Fadare O, et al. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-e14.
33. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005;29:295-304. (Pubitemid 40321964)